Watch to see how V-Go may help address your type 2 diabetes patients’ insulin needs.
V-Go is indicated for use in adult patients requiring insulin. A U-100 fast-acting insulin should be used with V-Go. Humalog® (insulin lispro [rDNA origin] injection) and NovoLog® (insulin aspart [rDNA origin] injection) have been tested and found to be safe for use in V-Go. Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S. Individual results may vary
References: 1. Data from 2011 US Roper Diabetes Patient Market Study provided by GfK Custom Research LLC and distributed only with express written permission of GfK Custom Research LLC. This study is an annual survey of over 2,000 diabetes patients (n = 2,104 in 2011: 692 who use insulin) via telephone and internet. Confidential–Not for Distribution Without Permission from Zealand Pharma A/S and GfK Custom Research LLC. 2. Guerci B, Chanan N, Kaur S, Jasso-Mosqueda JG, Lew E. Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes. Diabetes Ther. 2019;10(2):437‐449. 3. Randlov J, Poulsen J. How much do forgotten insulin injections matter to hemoglobin A1c in people with diabetes? A simulation study. Diabetes Science Tech. 2008;2(2):229-235. 4. Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279-1284. 5. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299‐1307.